Immune Checkpoint Inhibitor Dose Adaptation During the COVID-19 Pandemic in Non-Small Cell Lung Cancer: a Single-Center Experience

Research output: Contribution to journalMeeting AbstractAcademic

Original languageEnglish
Pages (from-to)S849-S849
Number of pages1
JournalJournal of Thoracic Oncology
Volume16
Issue number10
Publication statusPublished - Oct-2021

Keywords

  • NSCLC
  • covid-19
  • immune checkpoint inhibitor

Cite this